The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of cosibelimab, an anti–PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.
 
Philip R. Clingan
No Relationships to Disclose
 
Daniel Brungs
No Relationships to Disclose
 
Susan Arnold
Research Funding - Excellentis Clinical Trial Consultants (Inst)
 
Jermaine Coward
Research Funding - AstraZeneca (Inst)
 
Samuel J. Fourie
Leadership - ICON Oncology
Stock and Other Ownership Interests - ICON Oncology
 
Dean Laurence Harris
Research Funding - Checkpoint Therapeutics
 
Andrii Kurochkin
Research Funding - ICON Clinical Research; KCR; MSD; PSI Pharma Support America; Roche
 
Rahul Ladwa
Honoraria - AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; MSD
Consulting or Advisory Role - AstraZeneca/MedImmune; Roche
Travel, Accommodations, Expenses - MSD
 
Niel Malan
Research Funding - Phoenix Pharmaceuticals
 
Andrew Michael Mant
Consulting or Advisory Role - Novartis; Roche
 
Margie McGrath
Consulting or Advisory Role - MSD
 
Vinay Sharma
Speakers' Bureau - Elekta
 
Hong Shue
No Relationships to Disclose
 
Andrea Tazbirkova
No Relationships to Disclose
 
James Oliviero
Employment - Checkpoint Therapeutics
Leadership - Checkpoint Therapeutics; Nuvectis Pharma
Stock and Other Ownership Interests - Checkpoint Therapeutics; Nuvectis Pharma
Travel, Accommodations, Expenses - Checkpoint Therapeutics
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Bayer; BeiGene; Eisai; GlaxoSmithKline; Pierre Fabre
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)